Air Force

Bilirubin tests as risk predictors for systemic lupus erythematosus and psoriatic arthritis

  • US Patent No. 6905880
  • Issued: June 14, 2005
  • Status: Expired
Medical & Biotechnology

A new method for predicting the risk of cancer morality, rheumatoid arthritis; systemic lupus erythematosus, psoriatic arthritis, and all-cause mortality is disclosed. The method uses serum bilirubin levels as indicator for such risks, lower serum bilirubin levels generally indicating increased risk and higher levels a decreased risk.

Do you have questions or need more information on a specific technology? Let's talk.

Contact Us